0.00
price down icon100.00%   -1.19
 
loading
Schlusskurs vom Vortag:
$1.19
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$662.00K
Nettoeinkommen (Verlust:
$-29.02M
KGV:
0.00
EPS:
-8.5
Netto-Cashflow:
$-12.54M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-76.19%
1J Leistung:
-86.10%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$1.19

Orgenesis Inc Stock (ORGS) Company Profile

Name
Firmenname
Orgenesis Inc
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ORGS's Discussions on Twitter

Vergleichen Sie ORGS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ORGS
Orgenesis Inc
0.00 0 662.00K -29.02M -12.54M -8.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
419.10 106.87B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
491.22 63.14B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
576.77 61.27B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
849.46 51.94B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
167.91 35.04B 398.11M -1.03B -868.57M -5.7032

Orgenesis Inc Stock (ORGS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2018-12-20 Eingeleitet Dawson James Buy

Orgenesis Inc Aktie (ORGS) Neueste Nachrichten

pulisher
Oct 20, 2025

Why Orgenesis Inc. (45O) stock remains top rated2025 Investor Takeaways & Expert Approved Momentum Ideas - newser.com

Oct 20, 2025
pulisher
Oct 17, 2025

In-Depth 2025 Common Warts Industry Forecast: Plan Your Strategy for 2034 Success - WhaTech

Oct 17, 2025
pulisher
Oct 16, 2025

Rising Sexually Transmitted Infection (STI) Rates Propel Growth In Genital Warts Market: Pushing the Bounda... - WhaTech

Oct 16, 2025
pulisher
Oct 15, 2025

Will Orgenesis Inc. (45O) stock benefit from infrastructure billJuly 2025 Patterns & Daily Technical Stock Forecast Reports - newser.com

Oct 15, 2025
pulisher
Oct 13, 2025

Can Orgenesis Inc. (45O) stock withstand sector downturnsJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com

Oct 13, 2025
pulisher
Oct 11, 2025

Orgenesis Presents Technology Update To FDA/CBER Experts - AOL.com

Oct 11, 2025
pulisher
Oct 09, 2025

Is Orgenesis Inc 45O a good long term investmentFibonacci Retracement Levels & Explosive Trading Portfolio - earlytimes.in

Oct 09, 2025
pulisher
Oct 03, 2025

Is Orgenesis Inc. (45O) stock a top pick for value investorsTrade Exit Report & Low Drawdown Trading Strategies - newser.com

Oct 03, 2025
pulisher
Oct 01, 2025

Why Institutions Believe Beeyu Overseas Limited Is Undervalued TodayStock Buyback Updates & High Profit Market Tips - earlytimes.in

Oct 01, 2025
pulisher
Sep 30, 2025

Orgenesis (NASDAQ:ORGS) and Oragenics (NYSE:OGEN) Critical Contrast - Defense World

Sep 30, 2025
pulisher
Sep 28, 2025

Orgenesis Faces Multiple Leadership Resignations in August - MSN

Sep 28, 2025
pulisher
Sep 17, 2025

Orgenesis subsidiary Theracell enters $1 million convertible loan agreement By Investing.com - Investing.com South Africa

Sep 17, 2025
pulisher
Sep 17, 2025

Orgenesis subsidiary Theracell enters $1 million convertible loan agreement - Investing.com India

Sep 17, 2025
pulisher
Sep 16, 2025

Orgenesis Subsidiary Secures Convertible Loan Agreement - TipRanks

Sep 16, 2025
pulisher
Sep 12, 2025

Riku Dining Group Ltd sees U.S. IPO of 2.3 million Class A ordinary shares - MarketScreener

Sep 12, 2025
pulisher
Sep 10, 2025

LB Pharmaceuticals raises $285 million in US IPO - MarketScreener

Sep 10, 2025
pulisher
Sep 10, 2025

Genital Warts Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential - Barchart.com

Sep 10, 2025
pulisher
Sep 09, 2025

Exclusive-Stablecoin issuer Figure Technologies set to upsize IPO as demand for crypto-related stocks soars, source says - MarketScreener

Sep 09, 2025
pulisher
Sep 07, 2025

Orgenesis’s Sharp Swings Define Its High-Risk Biotech Story - Finimize

Sep 07, 2025

Finanzdaten der Orgenesis Inc-Aktie (ORGS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$36.63
price down icon 1.03%
$86.17
price down icon 1.60%
$30.54
price down icon 7.93%
$107.95
price up icon 2.67%
biotechnology ONC
$318.59
price up icon 0.69%
$167.91
price up icon 1.30%
Kapitalisierung:     |  Volumen (24h):